Jim Simons
APGE icon

Jim Simons’s Apogee Therapeutics APGE Stock Holding History

Jim Simons’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-41,100
Closed -$1.78M – 3481
2025
Q2 		$1.78M Buy
+41,100
New +$1.56M ﹤0.01% 2181
2024
Q3 		– Sell
-156,204
Closed -$6.15M – 3510
2024
Q2 		$6.15M Buy
156,204
+67,504
+76% +$3.28M 0.01% 1181
2024
Q1 		$5.89M Buy
+88,700
New +$3.87M 0.01% 1309

Other funds holding APGE

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Jim Simons's APGE Position: Q3 2025 in Review

Jim Simons sold out of Apogee Therapeutics (APGE) in Q3 2025, closing a stake of 41,100 shares — an estimated $1.78M sold.

Jim Simons first reported a position in APGE in Q1 2024 and held it in 3 quarters. The position peaked at $6.15M in Q2 2024. 174 funds tracked by Wall St. Rank hold APGE as of Q3 2025.

  • Jim Simons reported no remaining Apogee Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Jim Simons sold 41,100 Apogee Therapeutics shares in Q3 2025, an estimated $1.78M.
  • Jim Simons first reported a position in Apogee Therapeutics in Q1 2024 and held it in 3 quarters.
  • Jim Simons's Apogee Therapeutics position peaked at $6.15M in Q2 2024.
  • 174 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q3 2025.

Based on Renaissance Technologies's 13F filing for Q3 2025, filed 13 Nov 2025.